DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-760/S-027

AstraZeneca Pharmaceuticals LP
Attention: Paula R. Clark
Director, Regulatory Affairs
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Dear Ms. Clark:

Please refer to your supplemental new drug application dated April 30, 2008, received April 30, 2008 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for TENORETIC, (atenolol/chlorthalidone) Tablets 50 mg and 100 mg.

This supplemental new drug application provides for revision of the labeling as follows:

1. In the first paragraph, second sentence of **WARNINGS/Cardiac Failure** section, the following text was deleted: "In patients who have congestive heart failure controlled by digitalis and/or diuretics, TENORETIC should be administered cautiously. Both digitalis and atenolol slow AV conduction."

2. In the third paragraph of **PRECAUTIONS/Drug Interactions** section, the following text has been deleted: "Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have potentiating effect on atrial-conduction time and induce negative inotropic effect."

3. In the **PRECAUTIONS/Drug Interactions** section, the following has been added: "Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers.

   Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers".

4. In the **PRECAUTIONS/Drug Interactions** section, the following language has been added in response to a request by the Agency for all beta-blockers in a letter dated May 12, 2007: "Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia."

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the structured printed labeling (SPL) submitted on April 30, 2008.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

If you have any questions, please call:

Dan Brum Pharm.D., MBA,
Regulatory Project Manager
(301) 796 0578.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

10/29/2008 10:17:03 AM